MaxWin International Holdings Limited (HKG:8513)
Hong Kong
· Delayed Price · Currency is HKD 0.1420
0.00 (0.00%)
Jun 13, 2025, 3:42 PM HKT
HKG:8513 Revenue
In the year 2024, MaxWin International Holdings had annual revenue of 10.46M SGD with 14.33% growth. MaxWin International Holdings had revenue of 2.80M in the quarter ending December 31, 2024.
Revenue
10.46M SGD
Revenue Growth
+14.33%
P/S Ratio
1.95
Revenue / Employee
118.85K SGD
Employees
88
Market Cap
116.22M HKD
Revenue Chart
* This company reports financials in SGD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.46M | 1.31M | 14.33% |
| Dec 31, 2023 | 9.15M | -4.75M | -34.18% |
| Dec 31, 2022 | 13.90M | -5.88M | -29.71% |
| Dec 31, 2021 | 19.77M | -3.43M | -14.79% |
| Dec 31, 2020 | 23.21M | 7.99M | 52.54% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 32.53B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| Innovent Biologics | 10.03B |
| JD Health International | 61.89B |
| WuXi Biologics | 19.87B |
| CSPC Pharmaceutical Group | 28.99B |
| Sino Biopharmaceutical | 30.72B |
| Akeso | 2.26B |